Welcome to our dedicated page for Impel Pharmaceuticals news (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals stock.
Impel Pharmaceuticals Inc. (symbol: IMPL) is a Seattle-based biopharmaceutical company dedicated to providing groundbreaking therapies for central nervous system (CNS) diseases. Their innovative approach leverages a proprietary nasal drug delivery system known as the POD™ device, which ensures consistent and predictable drug administration to the upper nasal cavity.
Impel's diverse product portfolio is focused on addressing significant unmet medical needs.
- INP104 (POD™ DHE) is in development for the acute treatment of migraine headaches.
- INP103 (POD™ Levodopa) aims to offer relief for Parkinson's disease patients.
- INP105 (POD™ Olanzapine) targets agitation associated with schizophrenia and bipolar disorders.
- INP102 (POD™ Insulin) is being tested in an NIH-funded trial for Alzheimer's disease.
In September 2021, Impel received FDA approval for Trudhesa®, a nasal spray specifically designed for the acute treatment of migraine with or without aura in adults. This marks a significant milestone in their journey to provide effective therapies for CNS conditions.
Despite recent achievements, Impel has encountered financial challenges and has filed for Chapter 11 bankruptcy as part of a strategic decision to maximize value for stakeholders. The company is actively pursuing a sale and has entered into an agreement with JN BIDCO LLC as the 'stalking horse' bidder. Throughout this process, Impel aims to continue operating normally, ensuring minimal disruption to its customers, employees, and other key stakeholders.
For more details, visit Impel Pharmaceuticals Inc.
Impel Pharmaceuticals (NASDAQ: IMPL) reported strong growth for Trudhesa® in 2022 with over 58,400 prescriptions and a net product revenue of $12.7 million, a significant increase of 62% in Q4 compared to Q3. The company’s strategic expansion of its sales force in mid-2022 contributed to a 19.4% quarter-over-quarter rise in new prescriptions. However, net losses were substantial at $23 million for Q4 and $106.3 million for the full year. Despite these losses, Impel projects Trudhesa prescriptions to reach between 80,000 and 110,000 in 2023, signaling positive growth potential.
Impel Pharmaceuticals Inc. (NASDAQ: IMPL) will host a live webcast on March 24, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. This event will also provide a business update, highlighting the company’s focus on developing transformative therapies for unmet medical needs. Impel's FDA-approved product, Trudhesa® nasal spray, is designed for acute migraine treatment. Additionally, the company continues to explore partnerships and licensing opportunities to address patient needs.
Impel Pharmaceuticals (NASDAQ: IMPL) announced its participation in two investor conferences in March 2023. The 43rd Annual TD Cowen Health Care Conference will feature a fireside chat with CEO Adrian Adams on March 8 at 11:10 a.m. ET, held in Boston, MA. Following this, the 2nd Annual Needham Virtual Neuroscience Forum will take place on March 15 at 3:20 p.m. ET, also with Adams participating. Live webcasts of both events will be accessible on the company's Investor Relations webpage, with replays available for 90 days afterward. Impel is committed to developing innovative therapies for high unmet medical needs, exemplified by its FDA-approved Trudhesa nasal spray for migraine treatment.
Impel Pharmaceuticals (NASDAQ: IMPL) announced a strategic operational streamlining plan due to rising costs, resulting in a 16% reduction of its workforce and the discontinuation of its INP105 research program. The company aims to refocus resources on enhancing the commercial potential of its approved product, Trudhesa, which has shown a 58% increase in new prescriptions from Q2 to Q4 2022. Trudhesa has become a notable player in the acute migraine market, with over 58,424 prescriptions by year-end 2022. The company expects sufficient capital to support operations through Q3 2023 while it continues to explore strategic financing opportunities.
Impel Pharmaceuticals (NASDAQ: IMPL) reported strong growth in Q3 2022, with net product revenue for Trudhesa reaching $3.1 million and a 27% increase in prescriptions from Q2. Trudhesa now holds a market share of 5.2% in acute branded prescriptions, with over 48,600 prescriptions since its launch. The expanded sales force has driven a 58% increase in new patient starts. However, net losses rose to $31.8 million and SG&A expenses increased to $19.7 million. The company holds approximately $79.9 million in cash and equivalents.
Impel Pharmaceuticals (NASDAQ: IMPL) announced that Adrian Adams, CEO, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 1:00 p.m. ET in New York, NY. A live webcast of the event will be available on the company’s website, with a replay accessible for 90 days.
Impel Pharmaceuticals develops transformative therapies for diseases with high unmet needs, including the approved Trudhesa nasal spray for migraine treatment and the developing INP105 for agitation in autism.
Impel Pharmaceuticals (NASDAQ: IMPL) announced a live webcast on November 14, 2022, at 8:30 a.m. ET to disclose its third-quarter 2022 financial results and provide a business update. The webcast can be accessed through the company’s investor website. Impel is focused on creating transformative therapies for diseases with high unmet medical needs, including Trudhesa® for treating migraines and INP105 for managing agitation in autism patients.
Impel Pharmaceuticals (NASDAQ: IMPL) is set to participate in two investor conferences in September 2022. The first event is the H.C. Wainwright 24th Annual Global Investment Conference, where CEO Adrian Adams will engage in a fireside chat on September 13 at 5:00 p.m. ET. The second event is the Guggenheim Nantucket Therapeutics Conference, featuring John Leaman, M.D., on September 29 at 11:00 a.m. ET. Both discussions will be webcast live on the company's investor relations website, with a replay available for 90 days.
In Q2 2022, Impel Pharmaceuticals (NASDAQ: IMPL) reported a significant 48% growth in prescriptions for Trudhesa®, totaling over 13,000 TRx, with net product revenue rising 59% to $2.8 million compared to Q1 2022. The sales force expanded by 50% to enhance market penetration, while prescription guidance remains at 70-85K TRx for 2022. A proof-of-concept study for INP105 in autism spectrum disorder was initiated, underscoring the company’s commitment to addressing unmet medical needs. Impel reported a GAAP net loss of $25.2 million but maintains sufficient cash runway into 2024.
Impel Pharmaceuticals (NASDAQ: IMPL), a company focused on developing therapies for unmet medical needs, announced participation in the 2022 Wedbush PacGrow Healthcare Conference. CEO Adrian Adams and CFO John Leaman will engage in a fireside chat on August 9, 2022, at 12:35 p.m. ET. A live webcast will be accessible on their investor relations website, with a replay available for 90 days. Impel is known for its innovative treatments, including the Trudhesa® nasal spray for migraines and INP105 for autism-related agitation.
FAQ
What is the market cap of Impel Pharmaceuticals (IMPL)?
What is Impel Pharmaceuticals' core focus?
What is the POD™ device?
What is Trudhesa®?
What are the current products under investigation by Impel?
What recent financial steps has Impel taken?
Who is the 'stalking horse' bidder in Impel's sale process?
Will Impel continue its operations during the sale process?
Who is advising Impel during its restructuring?
Who is Impel's current Chief Restructuring Officer?
How can stakeholders get more information about the proceedings?
